JW Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

JW Asset Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-29,409	Closed	-$72K	–	30
2017 Q3	$72K	Hold	29,409	–	–	0.05%	29
2017 Q2	$372K	Hold	29,409	–	–	0.24%	30
2017 Q1	$309K	Hold	29,409	–	–	0.06%	36
2016 Q4	$271K	Hold	29,409	–	–	0.18%	29
2016 Q3	$347K	Sell	29,409 -121,229	-80%	-$1.84M	0.24%	29
2016 Q2	$1.95M	Sell	150,638 -70,900	-32%	-$1.03M	1.55%	17
2016 Q1	$3.54M	Sell	221,538 -129,440	-37%	-$2.46M	2.31%	13
2015 Q4	$10M	Sell	350,978 -37,368	-10%	-$1.04M	3.75%	10
2015 Q3	$11.1M	Buy	388,346 +3,702	+1%	+$136K	4%	8
2015 Q2	$13.8M	Buy	384,644 +10,408	+3%	+$324K	4.2%	7
2015 Q1	$10.9M	Sell	374,236 -7,818	-2%	-$207K	4.7%	8
2014 Q4	$8.05M	Buy	+382,054	New	+$7.55M	6.05%	7

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JW Asset Management's INSY Position: Q4 2017 in Review

JW Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 29,409 shares — an estimated $72K sold.

JW Asset Management first reported a position in INSY in Q4 2014 and held it in 12 quarters. The position peaked at $13.8M in Q2 2015. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

JW Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
JW Asset Management sold 29,409 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $72K.
JW Asset Management first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
JW Asset Management's Insys Therapeutics, Inc. position peaked at $13.8M in Q2 2015.
112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on JW Asset Management's 13F filing for Q4 2017, filed 12 Feb 2018.